Browse the corpus

REFERENCES Au WY, Tam S, Fong BM, et al, “Determinants of Cerebrospinal Fluid Arsenic Concentration in Patients With Acute Promyelocytic Leukemia on Oral Arsenic Trioxide Therapy,” Blood , 2008, 112(9):3587-90. [PubMed 18703707 ] Concha G, Vogler G, Lezcano D, et al, “Exposure to Inorganic Arsenic Metabolites During Early Human Development,” Toxicol Sci , 1998, 44(2):185-90. [PubMed 9742656 ] Echaniz-Laguna A, Benoilid A, Vinzio S, et al, "Mitochondrial Myopathy Caused by Arsenic Trioxide Therapy," Blood , 2012, 119(18):4272-4. [PubMed 22427206 ] Estey E, Garcia-Manero G, Ferrajoli A, et al, “Use of All-Trans Retinoic Acid Plus Arsenic Trioxide as an Alternative to Chemotherapy in Untreated Acute Promyelocytic Leukemia,” Blood , 2006, 107(9):3469-73. [PubMed 16373661 ] Fox E, Razzouk BI, Widemann BC, et al, “Phase 1 Trial and Pharmacokinetic Study of Arsenic Trioxide in Children and Adolescents With Refractory or Relapsed Acute Leukemia, Including Acute Promyelocytic Leukemia or Lymphoma,” Blood , 2008, 111(2):566-73. [PubMed 17959855 ] Gore SD, Gojo I, Sekeres MA, et al, “Single Cycle of Arsenic Trioxide-Based Consolidation Chemotherapy Spares Anthracycline Exposure in the Primary Management of Acute Promyelocytic Leukemia,” J Clin Oncol , 2010, 28(6):1047-53. [PubMed 20085935 ] IOM (Institute of Medicine), Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc , Washington, DC: National Academy Press, 2001, 162-84. Mathews V, George B, Chendamarai E, et al, “Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Long-Term Follow-Up Data,” J Clin Oncol , 2010, 28(24):3866-71. [PubMed 20644086 ] Mathews V, George B, Lakshmi KM, et al, “Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Durable Remissions With Minimal Toxicity,” Blood , 2006, 107(7):2627-32. [PubMed 16352810 ] National Comprehensive Cancer Network® (NCCN), “Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 3, 2010.” Available at file://www.nccn.org/professionals/physician_gls/PDF/aml.pdf

Mathews V, George B, Lakshmi KM, et al, “Single-Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia: Durable Remissions With Minimal Toxicity,” Blood , 2006, 107(7):2627-32. [PubMed 16352810 ] National Comprehensive Cancer Network® (NCCN), “Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 3, 2010.” Available at file://www.nccn.org/professionals/physician_gls/PDF/aml.pdf National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Powell BL, Moser B, Stock W, et al, “Arsenic Trioxide Improves Event-Free and Over-All Survival for Adults With Acute Promyelocytic Leukemia: North American Leukemia Intergroup Study C9710,” Blood , 2010, 116(19):3751-7. [PubMed 20705755 ] Powell BL, Moser B, Stock W, et al, “Effect of Consolidation With Arsenic Trioxide (As2O3) on Event-Free Survival (EFS) and Overall Survival (OS) Among Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL): North American Intergroup Protocol C9710,” J Clin Oncol , 2007, 25(18s):2 [abstract 2 from 2007 ASCO Annual Meeting]. Ravandi F, Estey E, Jones D, et al, “Effective Treatment of Acute Promyelocytic Leukemia With All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin,” J Clin Oncol , 2009, 27(4):504-10. [PubMed 19075265 ] Schiller GJ, Slack J, Hainsworth JD, et al, “Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes,” J Clin Oncol , 2006, 24(16):2456-64. [PubMed 16651647 ] Shen ZX, Chen GQ, Ni JH, et al, “Use of Arsenic Trioxide (As2O3) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients,” Blood , 1997, 89(9):3354-60. [PubMed 9129042 ] Soignet SL, Frankel SR, Douer D, et al, “United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia,” J Clin Oncol , 2001, 19(18):3852-60. [PubMed 11559723 ] Tallman MS and Altman JK, “How I Treat Acute Promyelocytic Leukemia,” Blood , 2008, 114(25):5126-35. [PubMed 19797519 ] Vey N, Bosly A, Guerci A, et al, “Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study,” J Clin Oncol , 2006, 24(16):2465-71. [PubMed 16651646 ]

Soignet SL, Frankel SR, Douer D, et al, “United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia,” J Clin Oncol , 2001, 19(18):3852-60. [PubMed 11559723 ] Tallman MS and Altman JK, “How I Treat Acute Promyelocytic Leukemia,” Blood , 2008, 114(25):5126-35. [PubMed 19797519 ] Vey N, Bosly A, Guerci A, et al, “Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study,” J Clin Oncol , 2006, 24(16):2465-71. [PubMed 16651646 ] Von Ehrenstein OS, Guha Mazumder DN, Hira-Smith M, et al, “Pregnancy Outcomes, Infant Mortality, and Arsenic in Drinking Water in West Bengal, India,” Am J Epidemiol , 2006,163(7):662-9. [PubMed 16651647 ] Yang CY, Chang CC, Tsai SS, et al, “Arsenic in Drinking Water and Adverse Pregnancy Outcome in an Arseniasis-Endemic Area in Northeastern Taiwan,” Environ Res , 2003, 91(1):29-34. [PubMed 12550085 ] Topic 8977 Version 42.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1103-200.131.240.2-31C67D9254-S244013.14]